Novartis Adds Myfortic To Transplant Portfolio
This article was originally published in The Pink Sheet Daily
Novartis gained approval for Myfortic (mycophenolate sodium) Feb. 27 for use in kidney transplantation
You may also be interested in...
The finding for the organ transplant drug follows by a month a similar warning about Roche competitor, CellCept.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.